Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation (Q43040073)

12 November 2017

title

Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation (English)

1 reference

12 November 2017

1 reference

3

1 reference

12 November 2017

Yoram Louzoun

4

0 references

author name string

Nora C Toussaint

series ordinal

1

1 reference

12 November 2017

Yaakov Maman

series ordinal

2

1 reference

12 November 2017

language of work or name

English

0 references

publication date

27 August 2011

1 reference

12 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

12 November 2017

volume

29

1 reference

12 November 2017

issue

47

1 reference

12 November 2017

page(s)

8745-8753

1 reference

HCV reinfection studies and the door to vaccine development.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Molecular pathogenesis of hepatitis C virus-associated hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

More than one reason to rethink the use of peptides in vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Stable Cytotoxic T Cell Escape Mutation in Hepatitis C Virus Is Linked to Maintenance of Viral Fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

The HIV hide and seek game: an immunogenomic analysis of the HIV epitope repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Phase-dependent immune evasion of herpesviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Viruses selectively mutate their CD8+ T-cell epitopes--a large-scale immunomic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

HIV vaccine development by computer assisted design: the GAIA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Antigenic Diversity Thresholds and the Development of AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Modelling the evolution and spread of HIV immune escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

MUSCLE: multiple sequence alignment with high accuracy and high throughput

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

7 January 2021

The IMGT/HLA database

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

IMGT/HLA database--a sequence database for the human major histocompatibility complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Precise score for the prediction of peptides cleaved by the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Towards in silico design of epitope-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

The neuraminidase of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Mutation trend of hemagglutinin of influenza A virus: a review from a computational mutation viewpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Characterization of ribosomal frameshifting in HIV-1 gag-pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Quantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Frequent toggling between alternative amino acids is driven by selection in HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.132

10.1016/J.VACCINE.2011.07.132

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference